June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer.
On the heels of successful patient treatments in Panama City, Panama, Francis Medical is overcoming challenges brought on by the COVID-19 pandemic to bring their ground-breaking water vapor technology to men dealing with prostate cancer.
October 16, 2019: Dr. Jonathan Jarow joins Francis Medical, Inc. as the company’s chief medical officer (CMO) to lead Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.
December 17, 2018: Francis Medical, Inc. has been featured in BioWorld MedTech, a leading news source of advances in medical technology.
December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy.
CAUTION: Investigational device. Limited by United States law to investigational use.
7351 Kirkwood Lane N., Suite 130, Maple Grove, MN 55369
Phone: 763-951-0370
Email: info@francismedical.com
Developing novel, disruptive therapeutic solutions to treat prostate, kidney and bladder cancer.
© Copyright Francis Medical, Inc. 2024 | ALL RIGHTS RESERVED | 4206-001_02